AMCP holds various meetings, forums, symposia, summits and other gatherings of experts to discuss topics of importance to managed care pharmacy. This section contains proceedings and findings and other documents that result from these events.
AMCP Partnership Forums bring together payers, pharmacies, integrated delivery system leaders, HEOR analysts, academics, providers, pharmaceutical manufacturers and various other health care stakeholders to discuss key issues facing managed care pharmacy and collaboratively help shape the changing health care landscape. The events are invitation only and are supported by our partners. The findings from the forums are shared with members via webinars and proceedings published in the Journal of Managed Care & Specialty Pharmacy.
- For past Partnership Forums, please visit Meeting Proceedings & Findings in our Resource Center.
- Learn more about sponsoring a Partnership Forum.
Partnership Forum — High Investment Medications
As novel therapies to address important medical needs are approved, the high costs for these medications — and especially cell and gene therapies — can raise sustainability and affordability concerns for employers, payers, and patients. High short-term investments present clinical and financial challenges that are magnified when the long-term health benefits are uncertain, patients switch employers or enroll in different health plans, or complex care coordination is needed. New payment policies and application of 21st century financial and technical tools can mitigate risk and affordability concerns. This Partnership Forum will address payment and benefit challenges for high-investment medications and explore alternative payment reform, financial tools, and policy initiatives to improve the predictability, affordability and accessibility of high-investment treatments and ensure patients get the medications they need at a cost they can afford.
Program Book [PDF]
April 26 - 27, 2022| Renaissance Arlington Capital View Hotel
Partnership Forum — Health Technology Assessment and Value Frameworks to Inform Coverage Reimbursement
In the transition from paying for the volume of health care to paying for value, health technology assessment (HTA) and value framework tools can serve as a resource for determining value of pharmaceuticals and other health interventions. Publicly available frameworks can provide valuable insights for health plans and PBMs as they evaluate appropriate use, coverage, and reimbursement for treatments. However, these tools must be based on sound methods using good scientific evidence and economic models, consider the totality of the evidence, incorporate the views of patients, and align value across stakeholders. This Partnership Forum will identify opportunities to improve how value assessments are developed and applied to formulary decision-making and provide strategies and guidance on best practices to equip managed care pharmacists and other professionals when applying these tools to assess value and optimize patient care.
August 30 - 31, 2022| Renaissance Arlington Capital View Hotel
ADVISORY GROUP — Addressing Barriers to Value-Based Payment Models in Integrated Delivery Networks
Collaborate with a group of key stakeholders to address how existing laws are impacting integrated delivery networks (IDNs) and pharmaceutical partnerships. Legal and regulatory requirements (e.g., the Anti-Kickback Statute and Medicaid best price rule) can limit the use of certain strategies that could potentially improve care coordination and patient outcomes. Successful implementation of value-based agreements in IDNs requires a range of complex capabilities. The workgroup will provide examples of real-world challenges and possible solutions that will inform and support efforts for legislative change.
ADVISORY GROUP — Substance Use Disorder: A Focus on Prescription Drug Use
Despite efforts to decrease the use of opioids, challenges remain. AMCP created multiple advisory groups beginning in 2015 recognizing the widespread and devastating nature of the opioid crisis. Over time, these groups addressed access to medications for treatment of substance use disorders and developed a viewpoint document on the importance of co-prescribing naloxone. The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address substance use disorder.
ADVISORY GROUP — Health Disparities
Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. As part of AMCP's strategic priority on addressing health disparities and commitment to transition from awareness to action, AMCP is committed to leveraging managed care pharmacy to address disparities in benefit design, medication use and outcomes in underserved populations. This advisory group will build upon the recommendations put forth during AMCP's 2021 Partnership Forum and will provide guidance as AMCP works to create awareness on the role of managed care professionals in this area, identify partners, and develop tools and resources to aid managed care pharmacy transition from awareness to action.
ADVISORY GROUP — Digital Therapeutics
The role of digital therapeutics in preventing, managing, and treating medical conditions continues to evolve, offering the potential for therapeutic benefit. AMCP is committed to leveraging managed care pharmacy to continue to evolve the use of digital therapeutics to improve patient care and outcomes. This group will build upon the recommendations put forth during the pervious AMCP Partnership Forums and provide guidance to AMCP in its efforts to establish the leadership role of managed care pharmacy professionals in this area, identify potential partners, and assist in the creation and dissemination of tools and resources to enhance the coverage and utilization of digital therapeutics.